Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR3 | Q99500 | 3/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 13/20 | 0.37 |
| ▸ | HTR3A | P46098 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12995078 | 0.96 | S1PR3 (0.39) | S1PR3HRH3HTR3AFAAHEPHX2 | |
| SCHEMBL12995244 | 0.91 | S1PR3 (0.39) | S1PR3HRH3DYRK1A | |
| SCHEMBL12995261 | 0.91 | S1PR3 (0.38) | S1PR3HRH3DYRK1A | |
| SCHEMBL12995221 | 0.88 | HRH3 (0.39) | S1PR3HRH3 | |
| SCHEMBL12995260 | 0.88 | HRH3 (0.38) | S1PR3HRH3DYRK1A | |
| SCHEMBL12995246 | 0.88 | S1PR3 (0.36) | S1PR3HRH3DYRK1A | |
| SCHEMBL13053211 | 0.87 | HRH3 (0.37) | S1PR3HRH3DYRK1A | |
| SCHEMBL12995218 | 0.87 | S1PR3 (0.38) | S1PR3HRH3DYRK1A | |
| SCHEMBL12995242 | 0.87 | MEN1 (0.40) | HTR3A | |
| SCHEMBL12995225 | 0.87 | HRH3 (0.37) | S1PR3HRH3DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-7772271-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772271-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-20070299068-A1 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. | 2007-12-27 | — | — | US | disclosed |
| US-20070299068-A1 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299068-A1 | Methods for treating hepatitis C | HAVCR2, EIF2AK2, MAVS | S1PR3 1968/4885HRH3 3336/4885HTR3A 4275/4885 |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, EIF2AK2, MAVS | S1PR3 1968/4885HRH3 3336/4885HTR3A 4275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.